MXPA01010588A - Medicamentos que contienen de la cinasa humana regulada por el volumen celular h-sgk. - Google Patents

Medicamentos que contienen de la cinasa humana regulada por el volumen celular h-sgk.

Info

Publication number
MXPA01010588A
MXPA01010588A MXPA01010588A MXPA01010588A MXPA01010588A MX PA01010588 A MXPA01010588 A MX PA01010588A MX PA01010588 A MXPA01010588 A MX PA01010588A MX PA01010588 A MXPA01010588 A MX PA01010588A MX PA01010588 A MXPA01010588 A MX PA01010588A
Authority
MX
Mexico
Prior art keywords
sgk
cell
human kinase
medicaments containing
regulated human
Prior art date
Application number
MXPA01010588A
Other languages
English (en)
Inventor
Karin Klingel
Original Assignee
Lang Florian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lang Florian filed Critical Lang Florian
Publication of MXPA01010588A publication Critical patent/MXPA01010588A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invencion se refiere a los medicamentos que contienen inhibidores o activadores de la cinasa humana h-sgk regulada por el volumen celular. Tales medicamentos son convenientes para el tratamiento de estados patologicos en los que se encuentra aumentada o reducida la expresion de h-sgk.
MXPA01010588A 1999-04-20 2000-04-19 Medicamentos que contienen de la cinasa humana regulada por el volumen celular h-sgk. MXPA01010588A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19917990A DE19917990A1 (de) 1999-04-20 1999-04-20 Arzneimittel enthaltend Hemmstoffe der zellvolumenregulierten humanen Kinase h-sgk
PCT/EP2000/003578 WO2000062781A1 (de) 1999-04-20 2000-04-19 Arzneimittel enthaltend hemmstoffe der zellvolumenregulierten humanen kinase h-sgk

Publications (1)

Publication Number Publication Date
MXPA01010588A true MXPA01010588A (es) 2004-09-06

Family

ID=7905297

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01010588A MXPA01010588A (es) 1999-04-20 2000-04-19 Medicamentos que contienen de la cinasa humana regulada por el volumen celular h-sgk.

Country Status (18)

Country Link
EP (1) EP1171131A1 (es)
JP (1) JP2002542196A (es)
KR (1) KR100718900B1 (es)
CN (1) CN1351496A (es)
AU (1) AU779941B2 (es)
BR (1) BR0009914A (es)
CA (1) CA2369078A1 (es)
CZ (1) CZ20013778A3 (es)
DE (1) DE19917990A1 (es)
HU (1) HUP0200819A3 (es)
MX (1) MXPA01010588A (es)
NO (1) NO20015054L (es)
PL (1) PL198427B1 (es)
RU (1) RU2288718C9 (es)
SK (1) SK14972001A3 (es)
UA (1) UA79066C2 (es)
WO (1) WO2000062781A1 (es)
ZA (1) ZA200108610B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10042137A1 (de) * 2000-08-28 2002-03-14 Florian Lang sgk2 und sgk3 als diagnostische und therapeutische Targets
DE10113876A1 (de) * 2001-03-21 2002-09-26 Eberhard Karls Uni Medizinisch Quantitative diagnostische Analyse der Hypertonie
DE60233398D1 (de) * 2001-04-27 2009-10-01 Cold Spring Harbor Lab Linderung der gedächtnisdefizite und gedächtniskomponenten von psychiatrischen funktionsstörungen durch veränderung der atypischen pkm-aktivität
DE10149393A1 (de) * 2001-09-28 2003-04-24 Florian Lang sgk1 als diagnostisches und therapeutisches target
DE10225844A1 (de) * 2002-06-04 2003-12-18 Lang Florian sgk und nedd als diagnostische und therapeutische targets
DE10305212A1 (de) * 2003-02-07 2004-08-19 Florian Prof. Dr.med. Lang Verwendung der sgk-Genfamilie zur Diagnose und zur Therapie von Katarakt und Glaukom
EP1613766A1 (de) * 2003-03-03 2006-01-11 Florian Physiologisches Institut I Lang Sgk1 als diagnostisches und therapeutisches target
WO2004084889A1 (en) * 2003-03-28 2004-10-07 Pfizer Inc. Use of protein kinase c inhibitor for suppressing sustained slow postsynaptic excitation (sspe) of enteric neurons
DE10346913A1 (de) 2003-10-09 2005-05-04 Merck Patent Gmbh Acylhydrazonderivate
WO2005084702A1 (ja) * 2004-03-02 2005-09-15 Hokkaido Technology Licensing Office Co., Ltd. 臓器線維症予防・治療剤
CN1929846A (zh) * 2004-03-11 2007-03-14 默克专利有限公司 包括采用血清和糖皮质激素诱导的激酶的调节物来调节谷氨酸受体以治疗神经精神障碍的方法
CA2559141A1 (en) * 2004-03-11 2005-10-13 Merck Patent Gesellschaft Mit Beschraenkter Haftung Methods for interfering with fibrosis
EP1745294A2 (en) * 2004-04-30 2007-01-24 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with serum/glucocorticoid regulated kinase 1 (sgk1)
WO2005118832A2 (en) * 2004-06-01 2005-12-15 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with serum/glucocorticoid regulated kinase-like protein (sgkl)
DE102004030987A1 (de) 2004-06-26 2006-01-12 Merck Patent Gmbh Ortho-substituierte (3-Hydroxyphenyl)-essigsäure-benzyliden-hydrazide
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
DE102005001053A1 (de) * 2005-01-07 2006-07-20 Merck Patent Gmbh Quadratsäurederivate
DE102005015255A1 (de) * 2005-04-04 2006-10-05 Merck Patent Gmbh Acylhydrazide
DE102005035742A1 (de) * 2005-07-29 2007-02-01 Merck Patent Gmbh Quadratsäurederivate II
DE102005039541A1 (de) * 2005-08-22 2007-03-22 Merck Patent Gmbh 3-Oxo-indazol-quadratsäurederivate
DE102007002717A1 (de) 2007-01-18 2008-07-24 Merck Patent Gmbh Heterocyclische Indazolderivate
DE102007022565A1 (de) 2007-05-14 2008-11-20 Merck Patent Gmbh Heterocyclische Indazolderivate
EP2014651A1 (en) * 2007-07-12 2009-01-14 Exonhit Therapeutics SA Compounds and methods for modulating Rho GTPases
DE102008010363A1 (de) 2008-02-18 2009-08-20 Lang, Florian, Prof. Dr.med. Sgk1 als therapeutisches und diagnostisches Target für karzinomatöse Erkrankungen
DE102008010362A1 (de) 2008-02-18 2009-08-20 Florian Prof. Dr. Lang Sgk1 als therapeutisches und diagnostisches Target für virale Erkrankungen
DE102008010361A1 (de) 2008-02-18 2009-08-20 Merck Patent Gmbh sgk1-Inhibitoren zur Prophylaxe und/oder Therapie von viralen Erkrankungen und/oder Karzinomen
DE102008029072A1 (de) * 2008-06-10 2009-12-17 Lang, Florian, Prof. Dr.med. Sgk3 als therapeutisches und diagnostisches Target für Alterserkrankungen
DE102008038220A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Oxadiazolderivate
DE102008038222A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Indazol-5-carbonsäurehydrazid-derivate
DE102008038221A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh 7-Azaindolderivate
DE102008059133A1 (de) 2008-11-26 2010-05-27 Merck Patent Gmbh Difluorphenyl-diacylhydrazid-derivate
WO2012064981A2 (en) * 2010-11-10 2012-05-18 National Jewish Health Methods to test allergic conditions
CN107875153A (zh) * 2017-11-16 2018-04-06 上海壹志医药科技有限公司 去甲白屈菜红碱的药物用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5373501A (en) * 1976-12-11 1978-06-30 Kitasato Inst Novel antibiotics amm2282 and process for preparing same
US5242397A (en) * 1989-06-20 1993-09-07 Cedars-Sinai Medical Center Catheter device and method of use for intramural delivery of protein kinase C and tyrosine protein kinase inhibitors to prevent restenosis after balloon angioplasty
US5137912A (en) * 1991-01-28 1992-08-11 National Science Council Of Republic Of China Chelerythrine inhibits platelet aggregation--a potential anti-aggregation drug
GB9325395D0 (en) * 1993-12-11 1994-02-16 Ciba Geigy Ag Compositions
US5874464A (en) * 1995-01-13 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Conformationally constrained diacylglycerol analogues
AU6888196A (en) * 1995-08-11 1997-03-12 Yale University Glycosylated indolocarbazole synthesis
AU737073B2 (en) * 1996-05-30 2001-08-09 Aventisub Ii Inc. Alkyloxyamino substituted fluorenones and their use as protein kinase C inhibitors
EP0887081B1 (en) * 1997-06-27 2003-04-23 Smithkline Beecham Corporation Human serum glucocorticoid regulated kinase, a target for chronic renal disease and diabetic nephropathy
EP0889127A1 (en) * 1997-07-01 1999-01-07 Smithkline Beecham Corporation Serine/threonine protein kinase (H-SGK2)
CO4940430A1 (es) * 1997-07-07 2000-07-24 Novartis Ag Compuestos policiclicos que contienen estaurosporina hidrogenada con propiedades farmacologicas convenientes y un efecto inhibidor sobre el crecimiento de las celulas tumorales

Also Published As

Publication number Publication date
EP1171131A1 (de) 2002-01-16
WO2000062781A1 (de) 2000-10-26
PL198427B1 (pl) 2008-06-30
ZA200108610B (en) 2002-01-02
CA2369078A1 (en) 2000-10-26
KR100718900B1 (ko) 2007-05-17
HUP0200819A3 (en) 2009-08-28
DE19917990A1 (de) 2000-11-02
UA79066C2 (en) 2007-05-25
CZ20013778A3 (cs) 2002-06-12
RU2288718C9 (ru) 2008-04-27
CN1351496A (zh) 2002-05-29
AU779941B2 (en) 2005-02-17
AU4297200A (en) 2000-11-02
PL352547A1 (en) 2003-08-25
SK14972001A3 (sk) 2002-06-04
JP2002542196A (ja) 2002-12-10
HUP0200819A2 (hu) 2002-07-29
RU2288718C2 (ru) 2006-12-10
NO20015054L (no) 2001-12-14
KR20020012172A (ko) 2002-02-15
NO20015054D0 (no) 2001-10-17
BR0009914A (pt) 2002-01-08

Similar Documents

Publication Publication Date Title
MXPA01010588A (es) Medicamentos que contienen de la cinasa humana regulada por el volumen celular h-sgk.
RS20050070A (en) Use of 1kb kinase inhibitors for the treatment of pain
TNSN05045A1 (en) Indole or benzimidazole derivatives for modulating ikappab kinase
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
AP1498A (en) Inhibitors of impdh enzyme.
PL341364A1 (en) 4-hydroxyqinoline-3-carboxamides and hydrazides as antiviral agents
AP9901478A0 (en) Compounds for the treatment of ischemia.
BG104780A (en) Inhibitors of phospholipase enzymes
GEP20063885B (en) Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
YU21702A (sh) Supstituisani indoli za moduliranje nfkb aktivnosti
HK1155944A1 (en) W-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
AP2000001996A0 (en) Heterocyclic inhibitors of P38.
IL154949A0 (en) Imidazole derivatives as raf kinase inhibitors
HK1091151A1 (en) Cosmetic use of a composition containing at least one oxazoline, serving as an active substance, as a slimming product and/or for preventing and/or treating cellulite
DE50310516D1 (de) Fredericamycin-derivate
UA66865C2 (uk) Інденопіролокарбазоли, фармацевтична композиція, спосіб інгібування кіназної активності та спосіб лікування (варіанти)
IL70882A0 (en) Certain benzazocinone and benzazoninone derivatives
YU8302A (sh) Upotreba cgrp-antagonista i cgrp-release-inhibitora za suzbijanje menopauznih toplotnih valunga
IL152097A0 (en) Use of pyrazole derivatives for treating infertility
TR200002203T2 (tr) Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi.
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
WO2002036578A3 (en) Triazine derivatives as lpaat-b inhibitors and uses thereof
MXPA04005809A (es) Inhibidores de proteinas quinasas.
MY120530A (en) Combination preparation for use in dementia

Legal Events

Date Code Title Description
FA Abandonment or withdrawal